

For Immediate Release

Contact: Erin Dunscomb
(312) 321-8224

SourceOne Global Partners Announces New US Patent For VESIsorb Technology

***Adds to global intellectual property protection for technology
in nutraceutical, pharmaceutical and cosmetic applications***

CHICAGO, IL – SourceOne Global Partners LLC. (“SourceOne”), a leading provider of health and wellness solutions created through scientific research and innovative product development, has announced that the VESIsorb® colloidal droplet delivery system has been awarded another U.S. patent, thus adding to its robust global intellectual property (IP) portfolio of patents and patents-pending.

This new U.S. patent number # 8,158,134 is described as an “umbrella patent” for the extensive coverage of a broad range of important natural product ingredients including but not limited to: Coenzyme Q10, QH Ubiquinol, Omega-3 EFAS, Vitamin D-3, resveratrol, curcumin, tocotrienols, citrus polymethoxylated flavones, eriocitrin (from citrus) and many more.

“The addition of this U.S. patent strengthens the security of our innovation platform and protects our many investments in clinical research. These include both science-backed ingredients and proprietary condition-specific formulations that utilize the VESIsorb colloidal droplet delivery system,” Jesse Lopez, founder and CEO of SourceOne Global Partners commented.

Multiple studies have demonstrated the benefits of the patented VESIsorb® delivery system, an innovation of Vesifact, a life science and drug delivery pioneer of Baar, Switzerland a spin-off from the Swiss Federal Institute of Technology, Zurich (ETH Zurich).

The peer-reviewed journal, *Alternative Therapies in Health and Medicine*, published the results of a double-blind study comparing the bioavailability of CoQ10 with VESIsorb® to that of other “bio-enhanced” CoQ10 formulations. In the study, entitled, “Relative Bioavailability Comparison of Different Coenzyme Q10 Formulations with a Novel Delivery System,” the relative bioavailability of a single oral dose of CoQ10 (CoQsource® exclusively from SourceOne) was assessed using the area under curve (AUC (0-10h)) where the value for CoQ10 with VESIsorb® reached 30.62 µg/ml/10h; a far superior 622% higher bioavailability than the oil-based formula. Furthermore, CoQ10 with VESIsorb® has higher plasma concentration levels over time.

A pharmacokinetic pilot study (single oral dose, crossover) in humans comparing Ubiquinol-QH to the same ubiquinol-QH in the VESIsorb® delivery system (CoQsource® QH exclusively from SourceOne) demonstrated an increase of 696% in peak blood levels (Cmax) of ubiquinol. The relative bioavailability calculated using the area under the curve (AUC_{0-24h}) was also increased by 485%.

Another pharmacokinetic pilot study (single oral dose, crossover) comparing absorption and bioavailability of Omega Choice® 90 concentrated EPA Omega-3 fish oil to the same Omega Choice® 90 in a VESIsorb® formulation demonstrated an increase of 567% in peak blood levels (cmax) of EPA in the formula that utilized the VESIsorb® colloidal droplet delivery system. The relative bioavailability calculated using the area under the curve (AUC0-12h) was also increased by 487%.

Marc Weder, CEO of Vesifact, explains, “This new US patent provides security as our growing pipeline of new VESIsorb formulations are being launched at a time when the marketplace is desperately in need of new clinically proven natural health and wellness solutions.”

Lopez comments, “Our brand partners benefit tremendously because their products formulated with VESIsorb® are patent-protected bio-enhanced formulations. These formulations build stronger brand equity with consumers seeking natural products that deliver optimal absorption and bioavailability.”

About SourceOne™ Global Partners

SourceOne Global Partners, headquartered in Chicago, IL, is a leading provider of health and wellness solutions, created through scientific research and innovative product development. The Company's focus is on clinically proven formulations, combined with technologically-advanced and patented delivery systems with applications in nutritional supplements, functional food and beverage, medical food, and personal care markets. The formulations are bundled in easily identifiable platforms that address condition-specific, consumer health concerns.

SourceOne is recognized as a frontrunner in delivering the best science nature has to offer through health solutions like the award-winning Cholesstrinol™ Family of Heart Healthy Formulas; Omega Choice® Concentrated Omega-3 EPA/DHA fish oil; CoQsource® and CoQsource® QH Ubiquinol Bio-Enhanced Coenzyme Q10; AlivEL®100 Eurycoma longifolia; and SterolSource® Phytosterols. The Company's product line, which continues to expand, also includes TocoSource® Palm Tocotrienols; GammaSource® Mixed Tocopherols; PMF-source® Citrus Flavonoids (PMF); and much more.

The SourceOne network of research and technology partners encompasses collaborations with Vesifact AG (Baar, Switzerland), Virun (Walnut, California), and Ingredients By Nature (Montclair, CA). Additional information about SourceOne Global Partners can be found at <http://www.source-1-global.com/>.

About Vesifact AG

A vital link between current research and private industry, Vesifact is a spin-off from the Swiss Federal Institute of Technology, Zurich (ETH Zürich). Innovative technology and know-how are developed in Vesifact's laboratories and upscaled at its production units. They are then applied to commercial

products before being transferred to the marketplace. In this way, Vesifact brings the latest know-how to exactly where it is most needed.

Vesifact produces carrier systems that take medical, nutraceuticals, and cosmetic substances to precisely the place where their effect is most essential. Vesifact thus fulfills ever-increasing requirements for innovative dosage forms and offers state-of-the-art solutions.